Medivir ́s Licensee, Tango Therapeutics, Has Discontinued Development of Its TNG348 Clinical Program
Medivir ́s Licensee, Tango Therapeutics, Has Discontinued Development of Its TNG348 Clinical Program
STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts.
斯德哥爾摩，2024 年 5 月 23 日 /PRNewswire/-- 專注於在未得到滿足的高醫療需求領域開發癌症創新療法的製藥公司Medivir AB（納斯達克斯德哥爾摩股票代碼：MVIR）今天宣佈，Medivir的被許可方Tango Therapeutics（納斯達克股票代碼：TNGX；Tango）宣佈，由於在最初的研究隊列中觀察到毒性，新型USP1抑制劑 TNG348 的1/2期臨床試驗即將終止。
TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor, for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers, and has been developed by Tango from the preclinical USP1 program licensed from Medivir in 2020. At present, Medivir has no additional information than what has been announced in Tango's press release:
TNG348 是一種新型的USP1（泛素特異性蛋白酶 1）抑制劑，用於治療 BRCA1/2 突變體和其他同源重組缺乏 (HRD) + 癌症，由 Tango 在 2020 年獲得 Medivir 許可的臨床前USP1項目中開發。目前，除了Tango新聞稿中宣佈的內容外，Medivir沒有其他信息：
The announcement by Tango Therapeutics has no impact on Medivir's focus and development efforts with its lead program fostroxacitabine bralpamide (fostrox) for the treatment of primary liver cancer (HCC). Medivir continues to maximize the momentum of the fostrox development program as it accelerates a number of critical activities to enable initiation of a pivotal phase 2b study with accelerated approval intent. If successful outcome of the planned study, fostrox has the potential to become the first approved treatment for HCC patients who have progressed on current first-line standard of care, a market valued at ~$2.5bn annually by 2028.
Tango Therapeutics的宣佈對Medivir的重點和開發工作沒有影響，其主要項目福斯特羅西他濱布拉帕米（fostrox）用於治療原發性肝癌（HCC）。Medivir繼續最大限度地發揮fostrox開發計劃的勢頭，因爲它加快了許多關鍵活動，以加快批准意圖啓動一項關鍵的2b期研究。如果計劃中的研究取得成功，fostrox有可能成爲第一種獲批准的針對肝癌患者的治療方法，這些患者在目前的一線護理標準上取得了進展，到2028年，該市場價值約爲25億美元。
For additional information, please contact;
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100.
E-mail: [email protected]
如需更多信息，請聯繫；
Medivir AB 首席財務官馬格努斯·克里斯滕森
電話：+46 8 5468 3100。
電子郵件：[電子郵件保護]
About Medivir
關於 Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. .
Medivir開發的創新藥物側重於未得到滿足的醫療需求很高的癌症。候選藥物針對的是可用療法有限或缺失的適應症領域，並且有很大的機會爲患者提供顯著改善。Medivir專注於開發氟沙西他濱布拉帕胺（fostrox），這是一種智能的靶向化療，旨在選擇性地治療肝癌細胞並最大限度地減少副作用。合作和夥伴關係是Medivir商業模式的重要組成部分，藥物開發由Medivir或合作進行。Medivir的股票（股票代碼：MVIR）在納斯達克斯德哥爾摩的小盤股名單上市。
This information was brought to you by Cision
這些信息是由 Cision 帶給你的
The following files are available for download:
以下文件可供下載：
|
Press release (PDF) |
|
新聞稿 (PDF) |
SOURCE Medivir
來源 Medivir
譯文內容由第三人軟體翻譯。